When tumors like melanoma form, the immune system mobilizes for war. White blood cells called lymphocytes rush to assault the tumor — but cancer has ways of disabling the immune system. Once the immune cells penetrate the area in and around the tumor, they can be caught in chemical snares that render them inert or exhausted, so they cease working.
But those immune cells still have the potential to kill cancer cells. For decades, scientists have been working on a therapy that harvests the immune cells from a patient’s tumor, grows an army of them in the billions in a lab, and releases them back into the patient. It’s called TIL, or tumor infiltrating lymphocyte therapy. The technique has long shown promise, but only in small observational studies.
Now, a randomized trial published in the New England Journal of Medicine offers evidence that experts say shows TIL therapy can work as a proof of concept, and that it can soundly beat out an approved immunotherapy for metastatic melanoma.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect